Digitoxin is a natural cardiac glycoside obtained from Digitalis purpurea, also known as the foxglove plant. It has been used for many years to treat heart failure and atrial fibrillation. The drug works by inhibiting the Na⁺/K⁺-ATPase pump, which increases the strength of heart contractions.
Because of its narrow therapeutic range, digitoxin can easily become toxic. This led to a decline in its regular clinical use. Today, researchers are studying digitoxin again for new purposes. It is being investigated for its anticancer, antiviral, and anti-inflammatory effects. Some studies suggest that it can slow tumor growth, control immune activity, and stop viral replication.
These findings raise new questions. Can digitoxin be reformulated to make it safer? Can it be used in new drug delivery systems or redesigned to create better cardiac glycosides?
Digitoxin shows that older medicines can still hold great potential when explored with modern scientific tools.
MBH/PS